Get access

Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib

Authors


Gene H. Kim, MD

1500 San Pablo Street, Los Angeles, CA 90033, USA

Tel: +1 323 442 9617

Fax: +1 323 442 9993

e-mail: genekim@usc.edu

Abstract

Vemurafenib is an inhibitor of BRAF and is used to treat patients with metastatic melanoma who carry a V600E BRAF mutation. Recently, four patients have been described in the literature who developed a neutrophilic panniculitis following treatment with a BRAF inhibitor. We present an additional case and review the clinical findings of the cases reported to date.

Get access to the full text of this article

Ancillary